Organization (Other)
University at Buffalo
ClinicalTrials.gov lists University at Buffalo as lead sponsor of 76 trials. It has 32 active development programs and 24 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo University at Buffalo, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University at Buffalo: 76 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (89)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 24 |
| Multiple Sclerosis | 19 |
| Obesity | 19 |
| Diabetes Mellitus, Type 2 | 12 |
| Diabetes Mellitus, Type 1 | 10 |
Showing 5 of 89 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 7 |
| 2020 | 6 |
| 2019 | 5 |
| 2018 | 11 |
| 2017 | 6 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: none of the 76 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (32)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| LIRAGLUTIDE | Diabetes Mellitus | Phase 3 | 7 |
| LIRAGLUTIDE | Diabetes Mellitus, Type 1 | Phase 3 | 7 |
| Dapagliflozin | Diabetes Mellitus, Type 1 | Phase 3 | 2 |
| Liraglutide 1.8mg | Diabetes Mellitus | Phase 3 | 1 |
| Liraglutide 1.8mg | Diabetes Mellitus, Type 1 | Phase 3 | 1 |
Showing 5 of 32 active programs.
Approved assets (24)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Testosterone | 3 |
| Dapagliflozin | 3 |
| Carvedilol Controlled Release (CR) | 1 |
| Exenatide Extended Release for Inj Susp 2 MG | 1 |
| androgel 10g | 1 |
Showing 5 of 24 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=34) | 63% on time (n=35) |
Journals published in (123)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of clinical endocrinology and metabolism | 6 |
| Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine | 5 |
| PloS one | 5 |
| Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 4 |
| Journal of cataract and refractive surgery | 4 |
Showing 5 of 123 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 1 | 2021-12-07 |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Charles University, Czech Republic | Co sponsors trial with | 2 |
| Teva Pharmaceuticals USA | Co sponsors trial with | 2 |
| Jacobs Neurological Institute | Co sponsors trial with | 1 |
| Teva Neuroscience, Inc. | Co sponsors trial with | 1 |
| Jeremy Greenlee | Co sponsors trial with | 1 |
Latest dated events (133)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 133 events.
Biomarker capability evidence (123)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC1 | Trial collaborator | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ADAM8 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 123 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.